Brief: Lefamulin NDA Filed In Mainland China For Treatment Of Community Acquired Pneumonia
29/11/2021 14:22
Nov 29 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* LEFAMULIN NDA FILED IN MAINLAND CHINA FOR TREATMENT OF
COMMUNITY
ACQUIRED PNEUMONIA
* NABRIVA THERAPEUTICS PLC - CO'S PARTNER, NDA HAS BEEN
ACCEPTED
FOR REVIEW BY CHINESE CENTER FOR DRUG EVALUATION ON NOV 23
Source text for Eikon: ID:nGNX6yTGPf
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update